Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis

From: Specialty Pharma Time By: Lauren Santye Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis Although there are a growing number of rheumatologists in the United States who report the use of Cosentyx to treat psoriatic arthritis (PsA), the increasing user base has failed to translate into overall increases in biologic share, [...]

Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis 2017-08-25T18:13:01+00:00

Early US dermatologist’s views of Tremfya leave ground to be covered

From: The Pharma Letter Early US dermatologist's views of Tremfya leave ground to be covered At two weeks post launch, only half of the surveyed US dermatologists (n=104) were aware of Tremfya's (guselkumab) approval when aided. The drug was approved by the US Food and Drug Administration on July 13 as a treatment for moderate [...]

Early US dermatologist’s views of Tremfya leave ground to be covered 2017-08-11T13:34:17+00:00